Two-Stage Tuberculin (PPD) Skin Testing in Individuals With Human Immunodeficiency Virus (HIV) Infection

NACompletedINTERVENTIONAL
Enrollment

864

Participants

Timeline

Start Date

Not specified

Primary Completion Date

December 31, 1992

Study Completion Date

December 31, 1992

Conditions
HIV InfectionsTuberculosis
Interventions
DRUG

Tuberculin Purified Protein Derivative

Administered intradermally at 5 TU per 0.1 mL

Trial Locations (14)

10011

Clinical Directors Network of Region II, New York

10037

Harlem AIDS Treatment Group / Harlem Hosp Ctr, New York

10456

Bronx Lebanon Hosp Ctr, The Bronx

11201

Addiction Research and Treatment Corp, Brooklyn

19899

Wilmington Hosp / Med Ctr of Delaware, Wilmington

20422

Veterans Administration Med Ctr / Regional AIDS Program, Washington D.C.

23298

Richmond AIDS Consortium, Richmond

48201

Comprehensive AIDS Alliance of Detroit, Detroit

48202

Henry Ford Hosp, Detroit

60657

AIDS Research Alliance - Chicago, Chicago

70112

Louisiana Comm AIDS Rsch Prog / Tulane Univ Med, New Orleans

97210

Portland Veterans Adm Med Ctr / Rsch & Education Grp, Portland

06519

Hill Health Corp, New Haven

07103

North Jersey Community Research Initiative, Newark

All Listed Sponsors
collaborator

Warner Lambert - Parke Davis

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00000955 - Two-Stage Tuberculin (PPD) Skin Testing in Individuals With Human Immunodeficiency Virus (HIV) Infection | Biotech Hunter | Biotech Hunter